Tyrosine kinase inhibitors (TKIs) have led to improvements in the management of non-small-cell lung cancer (NSCLC), though toxicity profiles of combined TKI and radiation therapies remains unclear.
We set out to determine if concurrent TKI therapy increases risk for acute esophageal or pulmonary toxicity following thoracic radiation.
